Key statistics dashboard for Elicio Therapeutics, Inc. (ELTX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers.
Stock Data
| Price | $1.77 |
| Market Cap | $34M |
| Beta | 1.88 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.85 |
| Price / Book | 4.36 |
| P/S | 0.00 |
| P/FCF | -0.91 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 2.77 |
| Quick Ratio | 2.77 |
| Cash Ratio | 2.55 |
| Debt / Equity | 1.78 |
| Debt / Assets | 45.16% |
| Interest Coverage | -24.00 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -13.92 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.41 |
| Cash per share | 1.22 |
| FCF per share | -1.96 |
| Tangible Book Value per share | 0.41 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 0.33 |
Related companies: ACTU · APLT · CRBP · CRDF · MIST · MOLN · NKTX
Explore sector: Healthcare · Biotechnology
More sections of ELTX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks